Evidence map›Paper›PMID 33628200›Full record

ArticleFrontiers in endocrinology2020

NEP-Score Thresholds Predict Survival of Patients With Bronchial Carcinoids.

Irene Gagliardi, Mario Tarquini, Maria Rosaria Ambrosio, Elisa Giannetta, Patricia Borges de Souza, Roberta Gafà, Aldo Carnevale, Paola Franceschetti, Maria Chiara Zatelli

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Irene GagliardiSection of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Mario TarquiniSection of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Maria Rosaria AmbrosioSection of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Elisa GiannettaSection of Medical Physiopathology, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Patricia Borges de SouzaSection of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Roberta GafàPathology Unit, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Aldo CarnevaleDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Paola FranceschettiEndocrine Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
Maria Chiara ZatelliSection of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
University of Ferrara · ITArcispedale Sant'Anna · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival prognostic markers are extremely needed to better define therapeutic strategies in patients with bronchial carcinoids (BC). We aim to verify the applicability of the NEP-Score in a homogeneous BC cohort and identify a derivative prognostic marker, the NEP-Score at diagnosis (NEP-D) that does not consider new metastases during follow-up. Sixty-four patients (38 females, and 26 males, mean age at diagnosis 58.9 ± 1.7 years) with BC were retrospectively evaluated. NEP-Score was calculated at the end of follow-up (NEP-T). A derivative score, the NEP-Score at diagnosis (NEP-D) that does not consider new metastases during follow-up, was then assessed. Patients were subdivided according to their living status at the end of follow-up. A NEP-Score threshold was investigated to predict survival. Mean NEP-T and mean NEP-D were significantly lower in live patients at end of follow-up. A NEP-T cut-off >138 significantly predicts survival. Atypical BC relapsed more frequently than Typical BC. Male gender and previous malignancy were negative prognostic factors for survival. We confirmed NEP-Score applicability in BC and NEP-D utility, being the latter a simple, quick, and cheap prognostic score that can help clinicians in decision making. The identified NEP-D threshold can predict NEN aggressiveness and may be used to define the best personalized therapeutic strategy. In this context, a validation study is needed.

Indexed as

AdultAgedAged, 80 and overBronchial NeoplasmsCarcinoid TumorCohort StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedNeuroendocrine CellsPrognosisRetrospective StudiesSurvival Ratebronchial neuroendocrine neoplasmsDelta NEP scoreNEP-DNEP-ScoreNEP-Tsurvival

Identifiers

PMID33628200
PMCPMC7897663
OpenAlexW3127432649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.